Search

Author/Creator Agulnik, M.

1. 3403 Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS). (September 2015)

Authors:
Patel, S.; Mehren, M. Von; Reed, D.; Agulnik, M.; Kaiser, P.; Charlson, J.; Kraft, A.; Hamm, J.; Karnad, A.; Ryan, C.; Rushing, D.; Meyer, C.; Khokhar, N.Z.; McCarthy, S.; Park, Y.C.; Knoblauch, R.E.; Parekh, T.V.; Maki, R.G.; Demetri, G.D.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S689
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas. (22nd October 2016)

Authors:
Agulnik, M.; Costa, R. L. B.; Milhem, M.; Rademaker, A. W.; Prunder, B. C.; Daniels, D.; Rhodes, B. T.; Humphreys, C.; Abbinanti, S.; Nye, L.; Cehic, R.; Polish, A.; Vintilescu, C.; McFarland, T.; Skubitz, K.; Robinson, S.; Okuno, S.; Van Tine, B. A.
Journal:
Annals of oncology
Issue:
Volume 28:Number 1(2017)
Page Start:
121
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search